Flunitrazepam (Rohypnol®) is a hypnotic and anesthetic induction agent available in several western European countries. Despite its clinical use throughout the world, Flunitrazepam has never been approved by the Food and Drug Administration for use in the United States. Recently, Flunitrazepam has become a problem in the United States due to illicit trafficking and an increase in recreational use. Most notably, the misuse of Flunitrazepam has been implicated with date rape in a number of U.S. cities. The detection of Flunitrazepam in urine is rare given its rapid and extensive biotransformation to the major urinary metabolite 7-aminoflunitrazepam and at least 10 other metabolites. To effectively detect the presence of this drug, this procedure specifically targets the Flunitrazepam metabolite, 7-aminoflunitrazepam.